OM:EKTA B
OM:EKTA BMedical Equipment

Elekta (OM:EKTA B) Valuation Check After FDA Clearance For Evo CT Linac Entry Into US Market

Elekta (OM:EKTA B) has attracted fresh attention after its Elekta Evo CT-Linac received FDA 510(k) clearance, opening the door for U.S. adoption of its AI supported imaging and radiation therapy platform. See our latest analysis for Elekta. The FDA clearance arrives at a time when Elekta’s share price has a 90 day share price return of 20.20% and a 30 day share price return of 6.47%, while the 1 year total shareholder return of a 2.89% decline and 5 year total shareholder return of a 40%...
OM:EMBRAC B
OM:EMBRAC BEntertainment

Embracer Group (OM:EMBRAC B) Valuation Check As Lee Guinchard Steps Up As Chief Operating Officer

Embracer Group (OM:EMBRAC B) has appointed long time games and entertainment executive Lee Guinchard as Chief Operating Officer, expanding his remit as the company reshapes itself into Fellowship Entertainment and refines how it uses key franchises. See our latest analysis for Embracer Group. Guinchard’s appointment comes after a difficult period for investors, with the share price at SEK 49.21 and a 90 day share price return showing a 52.24% decline, while the 1 year total shareholder return...
OM:IDLDX
OM:IDLDXLife Sciences

European Penny Stocks To Watch: 3 Picks With Market Caps Over €30M

The European market has shown resilience, with the STOXX Europe 600 Index gaining ground thanks to robust economic data and encouraging earnings results. Amid this backdrop, penny stocks—though often associated with speculative trading—remain a relevant investment area when backed by solid financials. These smaller or newer companies can offer a unique blend of affordability and growth potential, making them attractive options for investors seeking opportunities beyond the mainstream.
OM:CAMX
OM:CAMXPharmaceuticals

How FDA Review of Oclaiz Could Shape Camurus’ (OM:CAMX) Long-Term Endocrinology Strategy

Camurus AB (publ) recently announced that the U.S. FDA has accepted for review its resubmitted New Drug Application for Oclaiz (CAM2029), an extended-release octreotide injection for acromegaly, with a PDUFA target action date set for 10 June 2026. This acceptance helps clear a prior hurdle tied to third-party manufacturing observations and follows earlier EU and UK approvals and launch of the same product, marketed there as Oczyesa. We will now examine how FDA acceptance of the Oclaiz...
OM:NOBI
OM:NOBIConsumer Durables

Assessing Nobia (OM:NOBI) Valuation After UK Exit Plan And SEK 1.5b Rights Issue

Why Nobia’s rights issue and UK exit matter for shareholders Nobia (OM:NOBI) is overhauling its business by selling its UK operations, refocusing on Nordic markets, and raising approximately SEK 1.5b through a rights issue, together with new loan agreements and planned capital structure changes. See our latest analysis for Nobia. The rights issue, UK exit and refinancing have come against a weak share price backdrop, with a 7 day share price return of 27.12% decline and a 5 year total...
OM:TRUE B
OM:TRUE BSoftware

A Look At Truecaller (OM:TRUE B) Valuation After Fresh Share Buybacks And AGM Timing

Truecaller (OM:TRUE B) has completed another round of share repurchases, taking treasury holdings to 5.02%, with the buyback programme timed ahead of the company’s 2026 Annual General Meeting. See our latest analysis for Truecaller. Despite the latest buybacks, the share price has come under pressure, with a 1 day share price return of a 2.96% decline, a 7 day share price return of a 9.94% decline and a 90 day share price return of a 57.88% decline. The 1 year total shareholder return of a...